Eiam-Ong Somchai, Buranaosot Somphon, Eiam-Ong Somchit, Wathanavaha Arpar, Pansin Pongsuk
Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand.
J Ren Nutr. 2007 May;17(3):173-8. doi: 10.1053/j.jrn.2007.01.001.
The study objective was to examine the nutritional effect of nandrolone decanoate, an androgen derivative, in predialysis patients with chronic kidney disease (CKD).
This was a prospective and experimental study.
The study was performed at the institutional level of clinical care.
Twenty-nine predialysis patients with CKD, with a glomerular filtration rate between 5 and 30 mL/min and moderate to severe malnutrition, were included and randomly divided into control (n = 13) and nandrolone decanoate (NAN, n = 16) groups.
Patients in the control group received optimally conventional treatment of CKD. Patients in the NAN group, in addition to the conventional treatment, were intramuscularly injected with nandrolone decanoate at the dose of 100 mg per for 3 months.
Nutritional markers, including lean body mass (LBM), normalized protein catabolic rate, serum albumin, and lipids, were determined at baseline and 3-month periods.
Baseline parameters in both groups were not different. After 3 months, the patients in the NAN group had increased LBM (P < .01) and decreased serum albumin levels (P < .05), but no changes in the values of normalized protein catabolic rate, serum lipids, hematocrit, and glomerular filtration rate. No alterations in all parameters were identified in the control group. Changes in LBM in the NAN group were significantly higher than in the control group (P < .05). Minor adverse effects were observed in a few patients in the NAN group.
Nandrolone decanoate expresses an anabolic effect on LBM without altering the renal function and thus would provide nutritional benefit in predialysis patients with CKD.
本研究旨在探讨雄激素衍生物癸酸诺龙对慢性肾脏病(CKD)透析前患者的营养作用。
这是一项前瞻性实验研究。
该研究在临床护理机构层面进行。
纳入29例CKD透析前患者,肾小球滤过率在5至30 mL/分钟之间,伴有中度至重度营养不良,随机分为对照组(n = 13)和癸酸诺龙(NAN,n = 16)组。
对照组患者接受CKD的最佳常规治疗。NAN组患者除常规治疗外,还肌肉注射癸酸诺龙,剂量为每次100 mg,共3个月。
在基线和3个月时测定营养指标,包括瘦体重(LBM)、标准化蛋白分解代谢率、血清白蛋白和血脂。
两组基线参数无差异。3个月后,NAN组患者的LBM增加(P <.01),血清白蛋白水平降低(P <.05),但标准化蛋白分解代谢率、血清血脂、血细胞比容和肾小球滤过率的值无变化。对照组所有参数均无改变。NAN组LBM的变化显著高于对照组(P <.05)。NAN组少数患者观察到轻微不良反应。
癸酸诺龙对LBM有合成代谢作用,且不改变肾功能,因此可为CKD透析前患者提供营养益处。